Genomic analyses identify molecular subtypes of pancreatic cancer
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Integrated genomic analysis of 456 pancreatic ductal adenocarcinomas identified 32 recurrently mutated genes that aggregate into 10 pathways: KRAS, TGF-β, WNT, NOTCH, ROBO/SLIT signalling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing. Expression analysis defined 4 subtypes: (1) squamous; (2) pancreatic progenitor; (3) immunogenic; and (4) aberrantly differentiated endocrine exocrine (ADEX) that correlate with histopathological characteristics. Squamous tumours are enriched for TP53 and KDM6A mutations, upregulation of the TP63∆N transcriptional network, hypermethylation of pancreatic endodermal cell-fate determining genes and have a poor prognosis. Pancreatic progenitor tumours preferentially express genes involved in early pancreatic development (FOXA2/3, PDX1 and MNX1). ADEX tumours displayed upregulation of genes that regulate networks involved in KRAS activation, exocrine (NR5A2 and RBPJL), and endocrine differentiation (NEUROD1 and NKX2-2). Immunogenic tumours contained upregulated immune networks including pathways involved in acquired immune suppression. These data infer differences in the molecular evolution of pancreatic cancer subtypes and identify opportunities for therapeutic development.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KRAS G12D mutations are most commonly observed in pancreatic ductal adenocarcinoma (36%, [20]) and colorectal cancers (12%, [21]) and are also found in lung, endometrial and other cancers.”
From Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor (2022) · cites this paper as [20]
In the citing paper
“Importantly, a study conducted genomic analyses on pancreatic cancer, involving 456 tumors primarily of PDAC and its variants. The research identified 32 significantly mutated genes grouped into 10 molecular mechanisms, including KRAS mutations in 92% of cases.”
From Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer (2024) · cites this paper as [87]
In the citing paper
“The majority of KRAS mutations are at codon 12, with the highest prevalence of G12D mutation (35%), followed by G12V (20–30%), G12R (10–20%), Q61 (~5%), G12C (1–2%), and other rare muations9–12.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [11]
In the citing paper
“Amongst these are four canonical mutations – KRAS (~85%), TP53 (60–70%), CDKN2A (>50%), and SMAD4 (~50%).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [51]
In the citing paper
“the genomic landscape of PDAC is also dominated by loss of function alterations of TP53, SMAD4 (also known as DPC4), and CDKN2A45,48–50.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [50]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778
Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Cited by
Items 901–1,000 of 1,020
Ohara, Y., Tang, W., Liu, H., Yang, S., Dorsey, T. H., Cawley, H., Moreno, P., Chari, R., Guest, M., Azizian, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113434 · Cited by 45
Ellenrieder, V., König, A. O., & Seufferlein, T. T. W. (2016) · Digestion · doi:10.1159/000447739 · Cited by 38
Masetti, M., Acquaviva, G., Visani, M., Tallini, G., Fornelli, A., Ragazzi, M., Vasuri, F., Grifoni, D., Di Giacomo, S., Fiorino, S., et al. (2018) · Cancer Biomarkers · doi:10.3233/cbm-170464 · Cited by 38
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
Zhang, Y., Yang, C., Cheng, H., Fan, Z., Huang, Q., Yu, L., Fan, K., Luo, G., Jin, K., Wang, Z., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0551-7 · Cited by 45
“Ten distinct molecular mechanisms concerning 32 recurrently mutated genes were also identified and included KRAS, TGF-β, WNT, Notch, ROBO/ SLIT signaling, G1/S transition, SWI-SNF, chromatin modification, DNA repair, and RNA processing [4].”
BackgroundPrognostic stratification of resected pancreatic ductal adenocarcinoma: Past, present, and future
Barhli, A., Cros, J. F., Bartholin, L., & Neuzillet, C. (2018) · Digestive and Liver Disease · doi:10.1016/j.dld.2018.08.009 · Cited by 46
PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells
Marchand, B., Pitarresi, J. R., Reichert, M., Suzuki, K., Laczko, D. I., & Rustgi, A. K. (2019) · Oncogene · doi:10.1038/s41388-019-0725-6 · Cited by 42
“Study of the mutational landscape of pancreatic cancer has identified four molecular subtypes of pancreatic cancers (squamous, pancreatic progenitor, immunogenic and ADEX) and reaffirmed the importance of DNA repair pathways (49).”
BackgroundElarre, P. S., Oyaga-Iriarte, E., Yu, K. H., Baudin, V., Moreno, L. A., Carranza, O. E., Ortega, A. C., Ponz‐Sarvisé, M., Sosa, L., Rotellar, F., et al. (2019) · Cancers · doi:10.3390/cancers11050606 · Cited by 38
Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers
Arner, E. N., Du, W., & Brekken, R. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01049 · Cited by 44
Comparative bioinformatical analysis of pancreatic head cancer and pancreatic body/tail cancer
Yin, L., Xiao, L., Gao, Y., Wang, G., Gao, H., Peng, Y., Zhu, X., Wei, J., Miao, Y., Jiang, K., et al. (2020) · Medical Oncology · doi:10.1007/s12032-020-01370-0 · Cited by 39
Odyssey of trefoil factors in cancer: Diagnostic and therapeutic implications
Jahan, R., Shah, A., Kisling, S. G., Macha, M. A., Thayer, S. P., Batra, S. K., & Kaur, S. (2020) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188362 · Cited by 51
RAF1 rearrangements are common in pancreatic acinar cell carcinomas
Prall, O. W. J., Nastevski, V., Xu, H., McEvoy, C. R. E., Vissers, J. H. A., Byrne, D. J., Takano, E. A., Yerneni, S., Ellis, S. L., Green, T., et al. (2020) · Modern Pathology · doi:10.1038/s41379-020-0545-9 · Cited by 38
Self-citationMolecular and Metabolic Subtypes Correspondence for Pancreatic Ductal Adenocarcinoma Classification
Espiau-Romera, P., Courtois, S., Parejo-Alonso, B., & Sancho, P. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9124128 · Cited by 49
“[10] defined new molecular subtypes of PDAC based on comprehensive integrated genomic analysis and RNA expression profiles: “squamous”, “pancreatic progenitor”, “aberrantly differentiated endocrine exocrine” (ADEX) and “immunogenic” (Table 1).”
BackgroundInfluentialGenomic Heterogeneity of Pancreatic Ductal Adenocarcinoma and Its Clinical Impact
Gutiérrez, M. L., Muñoz‐Bellvís, L., & Órfão, A. (2021) · Cancers · doi:10.3390/cancers13174451 · Cited by 44
“Despite all different nomenclatures and subtypes proposed so far, all classifications consistently share two molecular subtypes of PDAC with unique, recurrently different, profiles (Supplementary Table S1): (i) a well-differentiated subgroup of tumors defined by expression of epithelial genes named classical [9,35,46,…”
BackgroundInfluentialCancer Stem Cells: Metabolic Characterization for Targeted Cancer Therapy
Kaur, J., & Bhattacharyya, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.756888 · Cited by 41
NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer
Doffo, J., Bamopoulos, S. A., Köse, H., Orben, F., Zang, C., Pons, M., den Dekker, A. T., Brouwer, R. W. W., Baluapuri, A., Habringer, S., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2105691119 · Cited by 38
Murphy, K. J., Chambers, C. R., Herrmann, D., Timpson, P., & Pereira, B. (2021) · Cancers · doi:10.3390/cancers13143481 · Cited by 45
“KRAS mutations are often considered the major driver during PDAC initiation being present in approximately 90% of PDAC patient tumors [13].”
BackgroundPiro, G., Carbone, C., Agostini, A., Esposito, A., Pizzol, M. D., Novelli, R., Allegretti, M., Aramini, A., Caggiano, A., Granitto, A., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02028-6 · Cited by 38
“classification) [31] from ARCNET Tissue Biobank (University of Verona) showing a compatible HLA with HIR mouse models (HuCD34-NSG) (Jackson Laboratory, USA).”
MethodSelf-citationPUREE: accurate pan-cancer tumor purity estimation from gene expression data
Revkov, E., Kulshrestha, T., Sung, K. W.-K., & Skanderup, A. J. (2023) · Communications Biology · doi:10.1038/s42003-023-04764-8 · Cited by 43
Cai, Y., & Wang, S. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae061 · Cited by 41
Brown, B. A., Myers, P. J., Adair, S. J., Pitarresi, J. R., Sah‐Teli, S. K., Campbell, L. A., Hart, W. S., Barbeau, M. C., Leong, K. M., Seyler, N. M., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-22-2945 · Cited by 45
Self-citationAyoub, M., Faris, C., Juranovic, T., Chela, H. K., & Daglilar, E. S. (2024) · Cancers · doi:10.3390/cancers16091625 · Cited by 41
Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
Ellrott, K., Wong, C. K., Yau, C. S. F., Castro, M. A. A., Lee, J., Karlberg, B., Grewal, J., Lagani, V., Tercan, B., Friedl, V., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2024.12.002 · Cited by 45
Self-citationThe Past, Present, and Future of Pancreatic Cancer Clinical Trials
Matrisian, L. M., & Berlin, J. D. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159117 · Cited by 37
The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
Sandhu, V., Wedge, D. C., Lothe, I. M. B., Labori, K. J., Dentro, S. C., Buanes, T. A., Skrede, M. L., Dalsgaard, A. M., Munthe, E., Myklebost, O., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0658 · Cited by 38
Thillai, K., Lam, H., Sarker, D., & Wells, C. M. (2016) · Oncotarget · doi:10.18632/oncotarget.13309 · Cited by 38
“A more recent genomic analysis of 456 early stage PDAC samples identified 32 genes that were recurrently mutated, each of which could be assigned to 10 pathways; KRAS, TGF- β, WNT, NOTCH, ROBO/SLIT signaling, G1/S transition, SWI-SNF, chromatin modification, DNA repair and RNA processing [22].”
Clinical study of genomic drivers in pancreatic ductal adenocarcinoma
Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.209 · Cited by 39
Self-citationHempel, S., Plodeck, V., Mierke, F., Distler, M., Aust, D. E., Saeger, H., Weitz, J., & Welsch, T. (2017) · Scientific Reports · doi:10.1038/s41598-017-08165-w · Cited by 37
Mutant p53R270H drives altered metabolism and increased invasion in pancreatic ductal adenocarcinoma
Schofield, H. K., Zeller, J., Espinoza, C. E., Halbrook, C. J., Vecchio, A. D., Magnuson, B., Fabo, T., Daylan, A. E. C., Kovalenko, I., Lee, H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.97422 · Cited by 44
“In pancreatic cancer, missense mutations are most common, although null alleles are occasionally observed (5, 9).”
BackgroundSelf-citationPing-Pong—Tumor and Host in Pancreatic Cancer Progression
Mu, W., Wang, Z., & Zöller, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01359 · Cited by 38
The dark side of immunotherapy: pancreatic cancer
Mucciolo, G., Roux, C., Scagliotti, A., Brugiapaglia, S., Novelli, F., & Cappello, P. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.13 · Cited by 41
“However, stratification based on tumor immunological background might identify those patients who will benefit from immunotherapy strategies in general([220]).”
BackgroundBeel, S., Kolloch, L. J., Apken, L. H., Jürgens, L., Bolle, A., Sudhof, N., Ghosh, S., Wardelmann, E., Meisterernst, M., Steinestel, K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17226-0 · Cited by 39
Panzeri, V., Manni, I., Capone, A., Naro, C., Sacconi, A., Agostino, S. D., de Latouliere, L., Montori, A., Pilozzi, E., Piaggio, G., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12847 · Cited by 34
Current Challenges for IDO2 as Target in Cancer Immunotherapy
Mondanelli, G., Mandarano, M., Belladonna, M. L., Suvieri, C., Pelliccia, C., Bellezza, G., Sidoni, A., Carvalho, A., Grohmann, U., & Volpi, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.679953 · Cited by 38
“Moreover, given the lack of information of a validated function, allocation of distinct profiles of IDO2 expression to the identified molecular subtypes of PDAC (45) cannot be performed yet.”
BackgroundDhara, S., Chhangawala, S., Chintalapudi, H., Aşkan, G., Aveson, V. G., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23237-2 · Cited by 39
Self-citationJanssen, B. V., Verhoef, S., Wesdorp, N. J., Huiskens, J., de Boer, O. J., Marquering, H. A., Stoker, J., Kazemier, G., & Besselink, M. G. (2021) · Annals of Surgery · doi:10.1097/sla.0000000000005349 · Cited by 36
“Inadequate patient selection for neoadjuvant and adjuvant treatment may lead to unnecessary treatment-related toxicity and suboptimal treatment for patients less sensitive to specific systemic regimens.(7,9,10) For surgical treatment, a ‘‘one-size-fits-all’’ treatment strategy may lead to a futile resection in some pa…”
BackgroundAutophagy Contributes to Metabolic Reprogramming and Therapeutic Resistance in Pancreatic Tumors
Reyes‐Castellanos, G., Hadi, N. A., & Carrier, A. (2022) · Cells · doi:10.3390/cells11030426 · Cited by 45
“More recently, several molecular classifications have been proposed on the basis of genomic and transcriptomic data, and currently they are well accepted [11,16,18].”
BackgroundThe impact of radiomics in diagnosis and staging of pancreatic cancer
Casà, C., Piras, A., D’Aviero, A., Preziosi, F., Mariani, S., Cusumano, D., Romano, A., Boškoski, I., Lenkowicz, J., Dinapoli, N., et al. (2022) · Therapeutic Advances in Gastrointestinal Endoscopy · doi:10.1177/26317745221081596 · Cited by 41
Early-onset pancreatic cancer: a review of molecular mechanisms, management, and survival
Ulanja, M. B., Moody, A. E., Beutler, B. D., Antwi‐Amoabeng, D., Rahman, G. A., & Alese, O. B. (2022) · Oncotarget · doi:10.18632/oncotarget.28242 · Cited by 48
Cancer-Associated Fibroblast Diversity Shapes Tumor Metabolism in Pancreatic Cancer
Peiffer, R., Boumahd, Y., Gullo, C., Crake, R., Letellier, E., Bellahcène, A., & Peulen, O. (2022) · Cancers · doi:10.3390/cancers15010061 · Cited by 38
“[65] divided PDAC patients into “squamous”, “pancreatic progenitor”, “immunogenic”, and “ADEX” subtypes.”
Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
Qunaj, L., May, M. S., Neugut, A. I., & Herzberg, B. O. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1252516 · Cited by 48
“KRAS mutations are among the most common activating mutations found in tumors, frequently present in non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), endometrial carcinoma, and colorectal carcinoma (CRC).”
BackgroundInfluentialDecoding the basis of histological variation in human cancer
Fujii, M., Sekine, S., & Sato, T. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00648-5 · Cited by 44
“For example, our own unpublished results indicate that the EZH2 inhibitor GSK-126 reduces the growth of organoids derived from pancreatic adenocarcinoma organoids, similar to what has been shown in prostate NEC 222 .”
Wang, Y., Yu, S., Huang, D., Cui, M., Hu, H., Zhang, L., Wang, W., Parameswaran, N., Jackson, M. W., Osborne, B. A., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2016.07.010 · Cited by 36
“12 Thus, targeting Notch pathway may represent a novel strategy for pancreatic cancer treatment.”
BackgroundMaina, S., Coutts, B. A., Edwards, O. R., de Almeida, L., Ximenes, A., & Jones, R. A. (2017) · Plant Disease · doi:10.1094/pdis-10-16-1499-re · Cited by 40
Cortese, N., Capretti, G. L., Barbagallo, M., Rigamonti, A., Takis, P. G., Castino, G. F., Vignali, D., Maggi, G., Gavazzi, F., Ridolfi, C., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0403 · Cited by 35
“org Cancer Immunol Res; 8(4) April 2020 499”
BackgroundInfluentialQiao, J., Chen, Y., Mi, Y., Jin, H., Huang, T., Liu, L., Gong, L., Wang, L., Wang, Q., & Zou, Z. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.05.069 · Cited by 40
Jeong, J., Kim, T., Kim, J., Choi, H. W., Kim, E. J., Yoo, H. J., Lee, S., Jun, H. R., Yoo, W., Kim, S., et al. (2020) · Cancers · doi:10.3390/cancers12092346 · Cited by 43
“improve the rate of early diagnosis and to establish a molecular-genomic landscape related to long-term survival [4,5].”
BackgroundDelving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In?
Tsang, E. S., Topham, J. T., Karasinska, J. M., Lee, M. K. C., Williamson, L., Mendis, S. R., Denroche, R. E., Jang, G. H., Kalloger, S. E., Moore, R. A., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1042 · Cited by 39
“Transcription factor FOXC2 shows increased expression in EOPC tumors Several transcriptome-based molecular subtypes of PDAC have been identified (10, 11, 13, 21) and shown to capture both intra(25) and intertumoral heterogeneity while providing prognostic significance.”
BackgroundMethodInfluentialThe SUMO pathway in pancreatic cancer: insights and inhibition
Schneeweis, C., Hassan, Z., Schick, M., Keller, U. B., & Schneider, G. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01119-6 · Cited by 42
“This observation is underscored by the demonstration that amplifications of MYC are positively selected for during tumour progression,(53) as well as the finding that MYC activity is associated with the basal-like subtype of the disease.(3,6) Therefore, targeting MYC and MYC-dependent pathways could offer opportunitie…”
ResultThe Tumor Microenvironment of Pancreatic Cancer
Karamitopoulou, E. (2020) · Cancers · doi:10.3390/cancers12103076 · Cited by 40
Creeden, J. F., Alganem, K., Imami, A. S., Brunicardi, F. C., Liu, S., Shukla, R., Tomar, T., Naji, F., & McCullumsmith, R. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228679 · Cited by 36
“PDCL5 Patient Derived Age: 56; Gender: Male; Ethnicity: Caucasian; Disease: Pancreatic Ductal Adenocarcinoma Surgical resection with or without post-surgical adjuvant therapy KRAS_G12V; TP53_G245S [7,9,11,108] Data Repo”
BackgroundLiu, M., Qin, Y., Hu, Q., Liu, W., Ji, S., Xu, W., Fan, G., Zeng, Y., Zhang, Z., Xu, X., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.023 · Cited by 37
Locally Advanced Pancreatic Ductal Adenocarcinoma: Challenges and Progress
Barcellini, A., Peloso, A., Pugliese, L., Vitolo, V., & Cobianchi, L. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s220971 · Cited by 41
Histone methylation in pancreatic cancer and its clinical implications
Liu, X., Guo, C.-H., Xi, Z.-Y., Xu, X.-Q., Zhao, Q.-Y., Li, L., & Wang, Y. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i36.6004 · Cited by 37
Cell Lineage Infidelity in PDAC Progression and Therapy Resistance
Malinova, A., Veghini, L., Real, F. X., & Corbo, V. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.795251 · Cited by 43
Self-citationPancreatic cancer: disease dynamics, tumor biology and the role of the microenvironment
Ansari, D., Frieß, H., Bauden, M. P., Samnegård, J., & Andersson, R. E. (2018) · Oncotarget · doi:10.18632/oncotarget.24019 · Cited by 38
“com/oncotarget molecular level [2, 34, 35], but still no subclassification has yet received clinical translation.”
BackgroundGu, M., Gao, Y., & Chang, P. (2021) · Cancers · doi:10.3390/cancers13102429 · Cited by 35
“Abbreviations ADM: acinar-to-ductal metaplasia; APC: adenomatous polyposis coli protein; ATM: ataxia telaniectasiamutated gene-coded protein; BRCA: breast cancer susceptibility gene; CAF: cancer-associated fibroblast; CCR: chemokine C-C motif receptor; CDKN2A: cyclin dependent kinase inhibitor 2A gene; CMS: consensus…”
BackgroundInfluentialDiehl, A. C., Hannan, L. M., Zhen, D. B., Coveler, A. L., King, G., Cohen, S. A., Harris, W. P., Shankaran, V., Wong, K. M., Green, S., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac179 · Cited by 35
Dendritic cells in pancreatic cancer immunotherapy: Vaccines and combination immunotherapies
Yang, J. Y., Shangguan, J., Eresen, A., Li, Y., Wang, J., & Zhang, Z. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152691 · Cited by 41
Flanagan, D. J., Woodcock, S. A., Phillips, C., Eagle, C., & Sansom, O. J. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108179 · Cited by 37
Self-citationSwietlik, J. J., Bärthel, S., Falcomatà, C., Fink, D., Sinha, A., Cheng, J., Ebner, S., Landgraf, P., Dieterich, D. C., Daub, H., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38171-8 · Cited by 43
George, B., Kudryashova, O. M., Kravets, A. D., Thalji, S. Z., Malarkannan, S., Kurzrock, R., Chernyavskaya, E. F., Gusakova, M., Kravchenko, D., Tychinin, D. I., et al. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.01.028 · Cited by 37
Loss of colonic fidelity enables multilineage plasticity and metastasis
Cammareri, P., Raponi, M., Hong, Y., Billard, C. V., Peckett, N., Zhu, Y., Velez-Bravo, F. D., Younger, N. T., Dunican, D. S., Pohl, S., et al. (2025) · Nature · doi:10.1038/s41586-025-09125-5 · Cited by 45
Self-citationLi, Y., Tang, S., Wang, H., Zhu, H., Lu, Y., Zhang, Y., Guo, S., He, J., Li, Y., Zhang, Y., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.07.008 · Cited by 53
Targeting tumor tolerance: A new hope for pancreatic cancer therapy?
Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 42
Yong, L.-K., Lai, S., Liang, Z., Poteet, E. C., Chen, F., Buren, G. V., Fisher, W. P., Mo, Q., Chen, C., & Yao, Q. C. (2016) · Oncotarget · doi:10.18632/oncotarget.13704 · Cited by 38
Self-citationFilipp, F. V. (2017) · Briefings in Functional Genomics · doi:10.1093/bfgp/elx001 · Cited by 41
Marchegiani, G., Andrianello, S., Perri, G., Secchettin, E., Maggino, L., Malleo, G., Bassi, C., & Salvia, R. (2017) · HPB · doi:10.1016/j.hpb.2017.10.017 · Cited by 36
Self-citationIntegrated Molecular Characterization of the Lethal Pediatric Cancer Pancreatoblastoma
Isobe, T., Seki, M., Yoshida, K., Sekiguchi, M., Shiozawa, Y., Shiraishi, Y., Kimura, S., Yoshida, M., Inoue, Y., Yokoyama, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2581 · Cited by 36
“Recent studies have suggested that adult 517 pancreatic tumors, such as PDAC (48,49), acinar cell carcinoma (50), and solid 518 pseudopapillary neoplasm (51), arise from committed precursors or mature cells of 519 acinar/ductal lineages through the mechanisms including dedifferentiation and 520 acinar-to-ductal metapl…”
BackgroundXPO1 Expression Is a Poor-Prognosis Marker in Pancreatic Adenocarcinoma
Birnbaum, D. J., Finetti, P., Birnbaum, D., Mamessier, É., & Bertucci, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050596 · Cited by 40
“We separately applied di ff erent multigene classifiers to each sample in each data set: the subtype classifiers that were reported by Bailey [61], Collisson [58], and Mo ffi tt [60], and the 25-gene prognostic signature that we recently developed [64].”
MethodFelix, T. F., Lapa, R. M. L., de Carvalho, M., Bertoni, N., Tokár, T., de Oliveira, R. A., Rodrigues, M. A. M., Hasimoto, C. N., de Oliveira, W. K., Pelafsky, L., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0217421 · Cited by 38
“immunogenic subtype of pancreatic cancer has been described [37], in which tumors harbor upregulated immune networks and distinct molecular pathways that may explain the evolution of this different disease subtype.”
BackgroundFraunhoffer, N. A., Abuelafia, A. M., Bigonnet, M., Gayet, O., Roques, J., Telle, E., Santofimia‐Castaño, P., Borrello, M. T., Chuluyán, E., Dusetti, N., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1232 · Cited by 39
“A centroid classifier approach was used for Chan-Seng-Yue (14), Collisson (9), and Bailey (8) subtype classification.”
MethodRecent advances in precision medicine for pancreatic ductal adenocarcinoma
Hayashi, H., Higashi, T., Miyata, T., Yamashita, Y., & Baba, H. (2021) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12436 · Cited by 39
“ADEX, aberrantly differentiated endocrine exocrine Classical Basal-like Quasimesenchymal Collisson et al. 2011 Moffitt et al. 2015 Bailey et al. 2016 Classical Exocrine-like Immunogenic Pancreatic progenitor ADEX Squamous Normal Activated Better WorsePrognostic outcome Stroma Cancer cell Puleo et…”
BackgroundTargeting Small GTPases and Their Prenylation in Diabetes Mellitus
Gendaszewska-Darmach, E., Garstka, M. A., & Błażewska, K. M. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00410 · Cited by 35
Urra, F. A., Fuentes-Retamal, S., Palominos, C., Rodríguez-Lucart, Y. A., López-Torres, C., & Araya‐Maturana, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.751301 · Cited by 41
“PDAC is associated with extensive matricellular fibrosis and more aggressiveness (Bailey et al., 2016; Tian et al., 2019; Papalazarou et al., 2020).”
BackgroundRecent advances in artificial intelligence for pancreatic ductal adenocarcinoma
Hayashi, H., Uemura, N., Matsumura, K., Liu, Z., Sato, H. R., Shiraishi, Y., Yamashita, Y., & Baba, H. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i43.7480 · Cited by 47
Principe, D. R. (2022) · Cancers · doi:10.3390/cancers14040897 · Cited by 42
“Though this approach offers a survival benefit to most patients, mounting evidence suggests that there are several genomically distinct PDAC subtypes, many of which may ultimately dictate therapeutic responses [3,4].”
BackgroundTargeting KRAS in PDAC: A New Way to Cure It?
He, Q., Liu, Z., & Wang, J. (2022) · Cancers · doi:10.3390/cancers14204982 · Cited by 45
“Cancers 2022, 14, x 2 of 16 endocrine exocrine (ADEX) [5].”
BackgroundClinico-genomic Characterization of ATM and HRD in Pancreas Cancer: Application for Practice
Park, W., O'Connor, C. A., Bandlamudi, C., Forman, D., Chou, J. F., Umeda, S., Reyngold, M., Varghese, A. M., Keane, F., Balogun, F., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1483 · Cited by 34
Self-citationDeciphering the roadmap of in vivo reprogramming toward pluripotency
Chondronasiou, D., Martínez de Villarreal, J., Melendez, E., Lynch, C. J., Pozo, N. D., Kovatcheva, M., Aguilera, M., Prats, N., Real, F. X., & Serrano, M. (2022) · Stem Cell Reports · doi:10.1016/j.stemcr.2022.09.009 · Cited by 34
“These keratins are not normally expressed in pancreas, except in the context of rare squamous pancreatic cancers (Bailey et al., 2016; Real et al., 1993).”
BackgroundInfluentialPietrobono, S., Sabbadini, F., Bertolini, M., Mangiameli, D., Vita, V. D., Fazzini, F., Lunardi, G., Casalino, S., Scarlato, E., Merz, V., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-0104 · Cited by 37
“The TGF b is the most recurrently mutated signal transduction pathway inPDAC(5).”
Ohyama, H., Hirotsu, Y., Amemiya, K., Mikata, R., Amano, H., Hirose, S., Oyama, T., Iimuro, Y., Kojima, Y., Mochizuki, H., et al. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.12.002 · Cited by 34
A mucus production programme promotes classical pancreatic ductal adenocarcinoma
Tonelli, C., Yordanov, G. N., Hao, Y., Deschênes, A., Hinds, J., Belleau, P., Klingbeil, O., Brosnan, E., Doshi, A., Park, Y., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-329839 · Cited by 40
Self-citationBhaw‐Luximon, A., & Jhurry, D. (2016) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-016-2178-4 · Cited by 35
“Recently, four molecular subtypes of pancreatic cancer have been identified: squamous (enriched for TP53 and KDM6A); pancreatic progenitor (expressing genes: FOXA2/3, PDX1 and MNX1); ADEX (genes involved in KRAS activation); and immunogenic tumors (Bailey et al. 2016).”
BackgroundRosati, L. M., Kumar, R., & Herman, J. M. (2017) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2017.02.005 · Cited by 34
Genomic Rearrangement Signatures and Clinical Outcomes in High-Grade Serous Ovarian Cancer
Hillman, R. T., Chisholm, G. B., Lu, K. H., & Futreal, P. A. (2017) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djx176 · Cited by 38
Lan, W., Bian, B., Xia, Y., Dou, S., Gayet, O., Bigonnet, M., Santofimia‐Castaño, P., Cong, M., Peng, L., Dusetti, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-26613-z · Cited by 39
Prognostic impact of Ki‐67 proliferative index in resectable pancreatic ductal adenocarcinoma
Pergolini, I., Crippa, S., Pagnanelli, M., Belfiori, G., Pucci, A., Partelli, S., Rubini, C., Castelli, P., Zamboni, G., & Falconi, M. (2019) · BJS Open · doi:10.1002/bjs5.50175 · Cited by 37
Hiroshima, Y., Kasajima, R., Kimura, Y., Komura, D., Ishikawa, S., Ichikawa, Y., Bouvet, M., Yamamoto, N., Oshima, T., Morinaga, S., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.10.031 · Cited by 41
Ramaker, R. C., Hardigan, A. A., Gordon, E. R., Wright, C., Myers, R., & Cooper, S. J. (2021) · BMC Cancer · doi:10.1186/s12885-021-08388-1 · Cited by 35
Metabolic therapy and bioenergetic analysis: The missing piece of the puzzle
Duraj, T., Carrión-Navarro, J., Seyfried, T. N., Garcia‐Romero, N., & Ayuso‐Sacido, Á. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101389 · Cited by 42
“In the same way, pancreatic cancer is an appealing target for metabolic intervention due to speci fi c metabolic subtypes, KRAS governance, mitochondrial defects, and generally poor prognosis [171,172].”
Aberrant RNA splicing and therapeutic opportunities in cancers
Yamauchi, H., Nishimura, K., & Yoshimi, A. (2021) · Cancer Science · doi:10.1111/cas.15213 · Cited by 38
Pancreatic cancer – the past, the present, and the future
Andersson, R. E., Haglund, C., Seppänen, H. E., & Ansari, D. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2067786 · Cited by 41
“[83] proposed four subtypes; squamous, pancreatic progenitor, immunogenic and aberrantly differentiated endocrine exocrine (ADEX).”
BackgroundLysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer
Santis, M. C. D., Gozzelino, L., Margaria, J. P., Costamagna, A., Ratto, E., Gulluni, F., Gregorio, E. D., Mina, E., Lorito, N., Bacci, M., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-325117 · Cited by 38
Self-citationMoving the Needle on Precision Medicine in Pancreatic Cancer
O'Kane, G. M., & Lowery, M. A. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02514 · Cited by 36
TP53 mutations predict poor response to immunotherapy in patients with metastatic solid tumors
Kim, J., Jung, J., Kim, K., Lee, J., & Im, Y. (2023) · Cancer Medicine · doi:10.1002/cam4.5953 · Cited by 38
Regulation of pancreatic cancer aggressiveness by stromal stiffening
Rath, N., & Olson, M. F. (2016) · Nature Medicine · doi:10.1038/nm.4099 · Cited by 40
Exosomes: novel implications in diagnosis and treatment of gastrointestinal cancer
Rahbari, M., Rahbari, N. N., Reißfelder, C., Weitz, J., & Kahlert, C. (2016) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-016-1468-2 · Cited by 37
Pellegata, N. S., Berriel Diaz, M., Rohm, M., & Herzig, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10058-y · Cited by 33
“been identified by integrated genomic analyses, one of them being the squamous subtype associated with mutations in TP53 and KDM6A [14].”
BackgroundQuadri, H. S., Aiken, T. J., Allgäeuer, M., Moravec, R., Altekruse, S. F., Hussain, S. P., Miettinen, M., Hewitt, S. M., & Rudloff, U. (2017) · BMC Cancer · doi:10.1186/s12885-017-3481-4 · Cited by 33
Pitter, K. L., Grbovic-Huezo, O., Joost, S., Singhal, A., Blum, M., Wu, K., Holm, M., Ferrena, A., Bhutkar, A. J., Hudson, A., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1742 · Cited by 40
Self-citation
Metadata
- Authors
- Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., Nourse, C., Murtaugh, L. C., Harliwong, I., Idrisoglu, S., Manning, S., Nourbakhsh, E., Wani, S., Fink, L., Holmes, O., Chin, V., Anderson, M. J., Kazakoff, S., Leonard, C., Newell, F., Waddell, N., Wood, S., Xu, Q., Wilson, P. J., Cloonan, N., Kassahn, K. S., Taylor, D., Quek, K., Robertson, A., Pantano, L., Mincarelli, L., Sanchez, L. N., Evers, L., Wu, J., Pinese, M., Cowley, M. J., Jones, M. D., Colvin, E. K., Nagrial, A. M., Humphrey, E. S., Chantrill, L. A., Mawson, A., Humphris, J., Chou, A., Pajic, M., Scarlett, C. J., Pinho, A. V., Giry-Laterriere, M., Rooman, I., Samra, J. S., Kench, J. G., Lovell, J. A., Merrett, N. D., Toon, C. W., Epari, K., Nguyen, N. Q., Barbour, A., Zeps, N., Moran-Jones, K., Jamieson, N. B., Graham, J. S., Duthie, F., Oien, K., Hair, J., Grützmann, R., Maitra, A., Iacobuzio-Donahue, C. A., Wolfgang, C. L., Morgan, R. A., Lawlor, R. T., Corbo, V., Bassi, C., Rusev, B., Capelli, P., Salvia, R., Tortora, G., Mukhopadhyay, D., Petersen, G. M., Initiative, A. P. C. G., Munzy, D. M., Fisher, W. E., Karim, S. A., Eshleman, J. R., Hruban, R. H., Pilarsky, C., Morton, J. P., Sansom, O. J., Scarpa, A., Musgrove, E. A., Bailey, U.-M. H., Hofmann, O., Sutherland, R. L., Wheeler, D. A., Gill, A. J., Gibbs, R. A., Pearson, J. V., Waddell, N., Biankin, A. V., & Grimmond, S. M.
- Affiliations
- The University of Queensland (AU)
- Garvan Institute of Medical Research (AU)
- Baylor College of Medicine (US)
- University of Utah (US)
- South Australia Pathology (AU)
- Harvard University (US)
- University of Glasgow (GB)
- Camden and Campbelltown Hospitals (AU)
- The University of Sydney (AU)
- UNSW Sydney (AU)
- Fiona Stanley Hospital (AU)
- Royal Adelaide Hospital (AU)
- Princess Alexandra Hospital (AU)
- The University of Western Australia (AU)
- Glasgow Royal Infirmary (GB)
- Beatson West of Scotland Cancer Centre (GB)
- NHS Greater Glasgow and Clyde (GB)
- Southern General Hospital (GB)
- Technische Universität Dresden (DE)
- The University of Texas MD Anderson Cancer Center (US)
- Johns Hopkins University (US)
- University of Verona (IT)
- Mayo Clinic (US)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Biankin, Andrew V.
- Grimmond, Sean M.
- ORCID
- Bailey, Peter
- Chang, David K.
- Johns, Amber L.
- Patch, Ann-Marie
- Gingras, Marie-Claude
- Christ, Angelika N.
- Quinn, Michael C.
- Murtaugh, L. Charles
- Harliwong, Ivon
- Manning, Suzanne
- Nourbakhsh, Ehsan
- Wani, Shivangi
- Holmes, Oliver
- Chin, Venessa
- Anderson, Matthew J.
- Kazakoff, Stephen
- Leonard, Conrad
- Newell, Felicity
- Wood, Scott
- Wilson, Peter J.
- Cloonan, Nicole
- Kassahn, Karin S.
- Quek, Kelly
- Robertson, Alan
- Pantano, Lorena
- Mincarelli, Laura
- Wu, Jianmin
- Pinese, Mark
- Cowley, Mark J.
- Jones, Marc D.
- Colvin, Emily K.
- Nagrial, Adnan M.
- Chantrill, Lorraine A.
- Mawson, Amanda
- Chou, Angela
- Pajic, Marina
- Scarlett, Christopher J.
- Pinho, Andreia V.
- Rooman, Ilse
- Samra, Jaswinder S.
- Kench, James G.
- Merrett, Neil D.
- Toon, Christopher W.
- Nguyen, Nam Q.
- Barbour, Andrew
- Zeps, Nikolajs
- Jamieson, Nigel B.
- Graham, Janet S.
- Oien, Karin
- Grützmann, Robert
- Maitra, Anirban
- Wolfgang, Christopher L.
- Lawlor, Rita T.
- Corbo, Vincenzo
- Bassi, Claudio
- Rusev, Borislav
- Salvia, Roberto
- Tortora, Giampaolo
- Petersen, Gloria M.
- Karim, Saadia A.
- Eshleman, James R.
- Hruban, Ralph H.
- Pilarsky, Christian
- Morton, Jennifer P.
- Sansom, Owen J.
- Scarpa, Aldo
- Bailey, Ulla-Maja Hagbo
- Hofmann, Oliver
- Wheeler, David A.
- Gill, Anthony J.
- Gibbs, Richard A.
- Pearson, John V.
- Waddell, Nicola
- Biankin, Andrew V.
- Grimmond, Sean M.
- Venue
- Nature
- Published
- 2016-02-24
- Volume
- 531
- Issue
- 7592
- Pages
- 47-52
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2285093314
- Cited by
- 3,621
- References
- 52
- Citations by year
- 2026: 247 · 2025: 347 · 2024: 311 · 2023: 404 · 2022: 430 · 2021: 504 · 2020: 397 · 2019: 307 · 2018: 295 · 2017: 257 · 2016: 117
- FWCI
- 175.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- UWA Profiles and Research Repository (UWA) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eSpace (Curtin University) (submittedVersion)
- Minerva Access (University of Melbourne) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- Pancreatic Cancer UK (RIF2015_A06_Jamieson)
- Wellcome Trust (103721/Z/14/Z)
- Cancer Research UK (C29717/A17263, A12481, 17263, A18076, 12946, 20409, 11650, 21139, 22533)
- Academy of Medical Sciences (AMS-SGCL9-Jamieson)
- Medical Research Council (MR/N005813/1)
- National Cancer Institute (P50CA062924)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- pancreatic ductal adenocarcinoma, molecular subtypes, recurrent mutations, KRAS, TP53, p63, KDM6A, DNA methylation, pancreatic progenitor cells, endocrine differentiation, immunosuppression, prognosis, transcriptional regulatory networks, histopathology
- MeSH terms
- Homeobox Protein Nkx-2.2, Animals, DNA-Binding Proteins, Humans, Mutation, Nuclear Proteins, Pancreatic Neoplasms, Prognosis, Transcription Factors, Transcription, Genetic, Trans-Activators, Genome, Human, Gene Expression Regulation, Neoplastic, Survival Analysis, Tumor Suppressor Protein p53, Receptors, Cytoplasmic and Nuclear, Homeodomain Proteins, DNA Methylation, Carcinoma, Pancreatic Ductal, Genomics, Tumor Suppressor Proteins, Zebrafish Proteins, Cell Line, Tumor, Mice, Hepatocyte Nuclear Factor 3-beta, Hepatocyte Nuclear Factor 3-gamma, Basic Helix-Loop-Helix Proteins, Genes, Neoplasm, Gene Regulatory Networks, Histone Demethylases, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.